+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Frontotemporal Disorder Treatment Market 2020-2026

  • PDF Icon


  • July 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5148089
Global Frontotemporal Disorder Treatment Market Size, Share & Trends Analysis Report by Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulant, Other) by Disease Type (Frontotemporal Dementia, Primary Progressive Aphasia, Movement Disorder) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) Forecast Period (2020-2026).

The frontotemporal disorder treatment market is anticipated to showcase a considerable growth rate during the forecast period. According to the World Health Organization (WHO), in 2017, there were an estimated 47.5 million people who have dementia with another 7.7 million new cases every year. The high prevalence of frontotemporal dementia across the globe is anticipated to create the demand for the frontotemporal disorder treatment market.

The frontotemporal disorder treatment market is segmented on the basis of drug class, disease type, and distribution channel. Based on the drug class, the market is segmented into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. Based on disease type, the market is segmented into frontotemporal dementia, primary progressive aphasia, and movement disorder. Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to hold a considerable market share in the frontotemporal disorder treatment market due to the high awareness of the drugs in the region. Asia-Pacific is the fastest-growing region in the market. The increasing prevalence of frontotemporal dementia in the emerging economies of Asia-Pacific is a key factor contributing to the growth of the market in the region.

The key players of frontotemporal disorder treatment market include Johnson & Johnson, Mylan N.V., Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Industries, Ltd., Eli Lily and Company, GlaxoSmithKline Plc., Novartis AG, Merck & Company, Inc., Allergen plc, F. Hoffmann-La Roche Ltd., and so on. The major players of the frontotemporal disorder treatment market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are driving the growth of the global frontotemporal disorder treatment market.

Research Methodology:

The market study of the global frontotemporal disorder treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Global Frontotemporal Disorder Treatment Market Research and Analysis by Drug Class
2. Global Frontotemporal Disorder Treatment Market Research and Analysis by Disease Type
3. Global Frontotemporal Disorder Treatment Market Research and Analysis by Distribution Channel

The Report Covers:
  • Comprehensive research methodology of the global frontotemporal disorder treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global frontotemporal disorder treatment market.
  • Insights about market determinants which are stimulating the global frontotemporal disorder treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global Frontotemporal Disorders Treatment Market by Drug Class
5.1.1. Cognitive Enhancers
5.1.2. Antipsychotics
5.1.3. Antidepressants
5.1.4. CNS Stimulant
5.1.5. Other
5.2. Global Frontotemporal Disorders Treatment Market by Disease Indication
5.2.1. Frontotemporal Dementia
5.2.2. Primary Progressive Aphasia
5.2.3. Movement Disorder
5.3. Global Frontotemporal Disorders Treatment Market by Distribution Channel
5.3.1. Hospital Pharmacies
5.3.2. Retail Pharmacies
5.3.3. Others
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Allergan PLC
7.2. Apotex Inc.
7.3. AstraZeneca PLC
7.4. Bausch Health Companies, Inc.
7.5. Eli Lily and Co.
7.6. F. Hoffmann-La Roche Ltd.
7.7. GlaxoSmithKline PlPLC
7.8. Intas Pharmaceutical Ltd.
7.9. Johnson & Johnson Service, Inc.
7.10. Merck & Company, Inc.
7.11. Mylan N.V.
7.12. Novartis AG
7.13. Pfizer, Inc.
7.14. Sanofi S.A.
7.15. Teva Pharmaceuticals Industries, Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Allergan PLC
  • Apotex Inc.
  • AstraZeneca PLC
  • Bausch Health Companies, Inc.
  • Eli Lily and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PlPLC
  • Intas Pharmaceutical Ltd.
  • Johnson & Johnson Service, Inc.
  • Merck & Company, Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals Industries, Ltd.